Due to the above reasons, decades of work have been invested into pre-clinical and six clinical trials addressing GDNF delivery as a potential treatment for Parkinson’s disease (PD), where striatal dopamine fibers and subsequently dopamine neurons in the midbrain substantia nigra gradually die. Here, GDNF is linked to Parkinson disease.